InnoTherapy Inc (246960) Fair Value & Analysis

Healthcare · KR · Market cap 54.5B KRW

Below-average quality, and screening another 76% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (718.77 KRW). The favourable scenario is already priced in.
• Weak quality (22/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range (359.39 KRW to 718.77 KRW) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.

How to read this chart

60‑month range 1,440 KRW – 4,463 KRW · fair‑value band 359.39 KRW – 718.77 KRW · the 1,994 KRW price screens above the 481.58 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 21, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

InnoTherapy Inc (246960) currently trades at 1,994 KRW, while our model-based Fair Value estimate is 481.58 KRW, implying the stock looks roughly 75.9% overvalued today. The Quality Score stands at 22/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, InnoTherapy Inc generated revenue of 27.4B KRW at a net margin of -11.6%. Revenue grew 237.9% year over year. It earns a return on equity of -13.3%. Net debt stands at 18.3B KRW. Fundamentals as of Jul 21, 2026

Our scenario range runs from 359.39 KRW (bear case) to 718.77 KRW (bull case); at 1,994 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 61% below its 52-week high and 24% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -33% fair-value upside, at -76%, 246960 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, …

Full company description

SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasis and sealing products; STOP, a non-bleeding intravascular injection; Film that prevents leakage at intestinal and vascular anastomosis sites; InnoLOCK and InTro vascular interventional procedure items; and operates bio-logistics business. The company also engages in conducting clinical trial analysis services related to new drug development, in vitro diagnostic medical device performance evaluation, transportation of pharmaceuticals and clinical trial samples, etc. The company was formerly known as InnoTherapy, Inc. and changed its name to SCL Science Inc. in March 2024. SCL Science Inc. was founded in 2010 and is headquartered in Seoul, South Korea.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

InnoTherapy Inc reported revenue of 22.0B KRW in FY2025 versus 507M KRW in FY2021, a compound +156.7%/yr. Reported net income was −3.9B KRW in FY2025.

246960 screens 76% overvalued. Compare with Abbott Laboratories, →

Peer Group

Medical Devices · 361 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Devices median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.